

#19

RECEIVED
CENTRAL FAX CENTER
AUG 29 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/615,872
Applicant : AREPALLY ET AL.
Filed : JULY 13, 2000
Title : COMPOSITIONS AND METHODS USEFUL FOR THE DIAGNOSIS
AND TREATMENT OF HEPARIN INDUCED
THROMBOCYTOPENIA/THROMBOSIS

Art Unit : 1641
Examiner : GRUN, JAMES L.

Atty Docket No. : UNME-0144-1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

OFFICIAL

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.51(b), 1.56, 1.97 and 1.98, this Information Disclosure Statement is submitted in the above-identified patent application. A listing of documents to be published on the face of any patent granted from this application is submitted herewith on Form PTO-1449. Any other documents or information submitted for consideration by the Examiner are listed in this paper. A copy of each U.S. and foreign patent, or each publication or portion thereof listed or herein identified, is submitted herewith, except that a copy of any U.S. patent application identified herein or any patent, publication or other information listed herein cited or submitted in a prior application relied upon for an earlier filing date under 35 U.S.C. § 120 and identified below, is not submitted herewith.

CERTIFICATION


This Supplemental Information Disclosure Statement is submitted after three months from (i) the filing date of the above-identified U.S. National Patent application, or (ii) after three months from entry into the U.S. National Stage of the above-identified International Application, or (iii) the date of entry into the U.S. National Stage of the International Application that has been assigned the above-identified U.S. Patent application number, whichever applies; and after the mailing date of the first Office Action on the merits of the above-identified application, but prior to issuance of the earlier of any Final Action or Notice of Allowance sent in such application. The certification under 37 C.F.R. § 1.97(e) is submitted separately or below, or the fee required under 37 C.F.R. § 1.97(c) and § 1.17(p) is submitted herewith.

Serial Number: 09/615,872

The Commissioner is hereby authorized to charge payment of any fees associated with this communication, including fees under 37 C.F.R. §§ 1.16 and 1.17 or credit any overpayment to **Deposit Account Number 10-0233-UNME-0144-1**.

The Examiner is requested to acknowledge consideration of the information provided in this paper in accordance with prescribed procedures.

Respectfully submitted,



Steven J. Prewitt

Registration Number 45,023

JAGTIANI + GUTTAG
Democracy Square Business Center
10363-A Democracy Lane
Fairfax, Virginia 22030
(703) 591-2664

July 17, 2003

Sheet 1 of 1

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NUMBER:	SERIAL NUMBER:
	UNME-0144-1	09/615,872
	APPLICANT:	
	AREPALLY <i>et al.</i>	
	FILING DATE:	GROUP:
	July 13, 2000	1641

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,466,582	Nov. 14, 1995	Amiral, Jean			

Foreign Patent Documents

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	Blank, <i>et al.</i> , <i>A mouse model for heparin-induced thrombocytopenia</i> , <i>Seminars In Hematology</i> , Vol. 36, No. 1, pp. 12-16, January 1999.
	Saggin, <i>et al.</i> , <i>Neutralization of the antiheparin activity of platelet factor 4 by a monoclonal antibody</i> , <i>Thrombosis and Haemostasis</i> , Vol. 67, No. 1, pp. 137-143, January 23, 1992.
	Arepally, <i>et al.</i> , <i>Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies</i> , <i>Blood</i> , Vol. 95, No. 5, pp. 1533-1540, March 1, 2000. (Abstract Only).
	Ma, <i>et al.</i> , <i>A murine model for heparin-induced thrombocytopenia (HIT)</i> , <i>Blood</i> , Vol. 94, No. 10, November 15, 1999. (Abstract Only).
	G.M. Arepally, <i>Characterization of a monoclonal antibody to PF4/heparin (KKO) with functional and serologic properties of HIT antibodies</i> , <i>Blood</i> , Vol. 94, No. 10, November 15, 1999.
	Ciaglowski, <i>et al.</i> , <i>Monoclonal antibodies to bovine platelet factor 4: species interactions to platelets and megakaryocytes using indirect immunocytofluorescence</i> , <i>Thrombosis Research</i> , Vol. 41, No. 6, March 15, 1986.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/615,872
Applicant : AREPALLY ET AL.
Filed : JULY 13, 2000
Title : COMPOSITIONS AND METHODS USEFUL FOR THE DIAGNOSIS AND
TREATMENT OF HEPARIN INDUCED
THROMBOCYTOPENIA/THROMBOSIS

Art Unit : 1641
Examiner : GRUN, JAMES L.

Atty Docket No. : UNME-0144-1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


LETTER

Sir:

The below-identified communication(s) is (are) submitted in the above-captioned application or proceeding:

- ☒ Supplemental Information Disclosure Statement
- ☒ Form 1449 w/references
- ☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication, including fees under 37 C.F.R. §§ 1.16 and 1.17 or credit any overpayment to Deposit Account Number 10-0233-UNME-0144-1.

Respectfully submitted,


Steven J. Prewitt
Registration Number 45,023

JAGTIANI + GUTTAG
Democracy Square Business Center
10363-A Democracy Lane
Fairfax, Virginia 22030
(703) 591-2664

July 17, 2003